Cancer metastasis—the spread of cancer to other organs—is the leading cause of death among cancer patients. Researchers have ...

Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of ...

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate ...

Cancer metastasis -- the spread of cancer to other organs -- is the leading cause of death among cancer patients. Researchers have now uncovered a 'genetic signature' of 177 genes shared across ...

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular ...

The field of cancer research is beginning to embrace a broader perspective that goes beyond genetic and molecular studies, recognizing the significant role ...

Cancer metastasis-the spread of cancer to other organs-is the leading cause of death among cancer patients. Researchers have now uncovered a "genetic signature" of 177 genes shared across multiple ...

An AI foundation model capable of predicting gene activity across many different human cell types may expedite research for ...

Yale researchers are sifting through a mosaic of cells in a living animal—both normal cells and mutated cells—to better ...

Over the past two decades, advances in the molecular genetics of MFS have enhanced our understanding, making FBN1 molecular testing essential in the clinical management of MFS and related connective ...